Drug profile · INN
isotretinoin
APO-ISOTRETINOIN
isotretinoin (APO-ISOTRETINOIN) is a retinoic acid receptor agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — isotretinoin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 5
- Programs
- 2
- Data quality
- 0.89
Quick answer
isotretinoin (APO-ISOTRETINOIN) is a retinoic acid receptor agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoic acid receptor agonist
Primary target: Retinoic acid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12005123
Conjugate of isotretinoin and peptide
granted -
US 11351266
Conjugate of isotretinoin and peptide
granted -
US 11219631
Foamable compositions, breakable foams and their uses
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11033491
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
granted
Frequently asked questions
What is isotretinoin?
isotretinoin (APO-ISOTRETINOIN) is a retinoic acid receptor agonist. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for isotretinoin?
APO-ISOTRETINOIN is a marketed brand name for isotretinoin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of isotretinoin?
isotretinoin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.